FDA Drug Safety Podcast for Healthcare Professionals: Revised dose limitation for Zocor (simvastatin) when taken with amiodarone
Narrator: Welcome to the FDA Drug Safety Podcast for Healthcare Professionals from the Division of Drug Information. Today’s topic: Revised dose limitation for Zocor (active ingredient simvastatin) when taken with amiodarone.
This update is in follow-up to the FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury on 6/8/2011.
Kimberly Wu, a pharmacist in the Division, will provide you with additional information about this Communication.
Guest Speaker: On December 15, 2011, the Food and Drug Administration issued a Drug Safety Communication notifying the public that it has revised the dose limitation for the cholesterol-lowering drug simvastatin from 10 mg to 20 mg when it is co-administered with the cardiac drug amiodarone. In June 2011, FDA previously recommended that the dose limitation for simvastatin be decreased from 20 mg to 10 mg, and has now reconsidered that recommendation.
In patients who are taking both simvastatin and amiodarone, the dose of simvastatin should not exceed 20 mg per day. The simvastatin drug labels (Zocor and generics and Vytorin) have been updated to reflect this correction.
In June 2011, FDA restricted the use of the highest approved dose of simvastatin (80 mg) to reduce the risk of myopathy. Therefore the 40-mg dose became the maximum safe dose of simvastatin. At the same time, FDA also proportionally lowered (i.e., a 50% reduction or more) all the maximum safe doses of simvastatin when it is taken with certain interacting drugs (i.e., drugs that can raise simvastatin blood levels). However, the simvastatin dose limitation when taken with amiodarone (in which the simvastatin dose was lowered from 20 mg to 10 mg) was made in error. Unlike other interacting drugs, there were no pharmacokinetic or clinical trial data to support the simvastatin dose reduction approved with amiodarone. Therefore FDA has determined that the simvastatin dose limitation, when taken with amiodarone, should be restored to 20 mg.
For a detailed discussion of the data that FDA evaluated, refer to page 33 of 216 in the FDA Review.
Narrator: Thank you for listening. The FDA is committed to keeping healthcare professionals informed of the latest safety information. A link to this communication, including a link to the FDA Review and the latest drug labels for simvastatin can be found at www.fda.gov/DrugSafetyCommunications. If you have drug questions, you can reach us at firstname.lastname@example.org.
Follow us on Twitter @FDA_Drug_Info for up to the minute important drug information. Know the moment it happens.